20212020201920182017201620152014 October 12, 2021 Summary ToggleSpero Therapeutics Appoints Kathleen Tregoning to its Board of Directors October 01, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 30, 2021 Summary ToggleSpero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million September 16, 2021 Summary ToggleSpero Therapeutics to Present Data at IDWeek 2021 September 07, 2021 Summary ToggleSpero Therapeutics to Present at Three Upcoming Investor Conferences August 31, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 05, 2021 Summary ToggleSpero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update July 30, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 29, 2021 Summary ToggleSpero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021 July 07, 2021 Summary ToggleSpero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference Pagination Current page 1 Page 2 Page 3 Next page Next Last page Last
